title: Blockade of L-type calcium channel in myocardium and calcium-induced contractions of vascular smooth muscle by CPU 86017.
abstract: OBJECTIVE
  To assess the blockade by CPU 86017 on the L-type calcium channels in the myocardium and on the Ca(2+)-related contractions of vascular smooth muscle.
  
  
  METHODS
  The whole-cell patch-clamp was applied to investigate the blocking effect of CPU 86017 on the L-type calcium current in isolated guinea pig myocytes and contractions by KCl or phenylephrine (Phe) of the isolated rat tail arteries were measured.
  
  
  RESULTS
  Suppression of the L-type current of the isolated myocytes by CPU 86017 was moderate, in time- and concentration-dependent manner and with no influence on the activation and inactivation curves. The IC(50) was 11.5 micromol/L. Suppressive effect of CPU 86017 on vaso-contractions induced by KCl 100 mmol/L, phenylephrine 1 micromol/L in KH solution (phase 1), Ca(2+) free KH solution ( phase 2), and by addition of CaCl(2) into Ca(2+)-free KH solution (phase 3) were observed. The IC(50) to suppress vaso-contractions by calcium entry via the receptor operated channel (ROC) and voltage-dependent channel (VDC) was 0.324 micromol/L and 16.3 micromol/L, respectively. The relative potency of CPU 86017 to suppress vascular tone by Ca(2+) entry through ROC and VDC is 1/187 of prazosin and 1/37 of verapamil, respectively.
  
  
  CONCLUSIONS
  The blocking effects of CPU 86017 on the L-type calcium channel of myocardium and vessel are moderate and non-selective. CPU 86017 is approximately 50 times more potent in inhibiting ROC than VDC.
authors.affiliation: Research Division of Pharmacology, China Pharmaceutical University, Nanjing, 210009, China. dezaidai@vip.sina.com
authors.forename: De-zai
authors.initials: DZ
authors.lastname: Dai
authors.forename: Hui-juan
authors.initials: HJ
authors.lastname: Hu
authors.forename: Jing
authors.initials: J
authors.lastname: Zhao
authors.forename: Xue-mei
authors.initials: XM
authors.lastname: Hao
authors.forename: Dong-mei
authors.initials: DM
authors.lastname: Yang
authors.forename: Pei-ai
authors.initials: PA
authors.lastname: Zhou
authors.forename: Cai-hong
authors.initials: CH
authors.lastname: Wu
mesh_terms: D000818:Animals; D001599:Berberine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology*; D002121:Calcium Channel Blockers / Q000494:pharmacology; D020746:Calcium Channels, L-Type / Q000187:drug effects*; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D005260:Female; D006168:Guinea Pigs; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects*; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D009206:Myocardium / Q000166:cytology / Q000378:metabolism*; D018408:Patch-Clamp Techniques; D051381:Rats; D017207:Rats, Sprague-Dawley; D013623:Tail / Q000098:blood supply
chemical_list: C400084:4-chlorobenzyltetrahydroberberine; D002121:Calcium Channel Blockers; D020746:Calcium Channels, L-Type; D001599:Berberine